Two breast cancer episodes over 15 years constrained broader life activities, underscoring how prolonged survivorship can narrow time, finances, and psychological reserve beyond direct medical demands ...

In an interview with CURE, Dr. Mark Zhao, a colorectal surgeon at UCSF Health specializing in colorectal cancer and pelvic floor disorders, discussed transanal minimally invasive surgery, the single ...

Follicular lymphoma survivorship carries enduring relapse vigilance; “risk drops” does not equate to baseline risk restoration even years after completing therapy. Small interval decreases in ...

Luciana Lopes Manfredini, BSN, PhD, of Einstein Hospital Israelita in São Paulo, Brazil, developed a triage scale for ...

In this installment of the balance exercise series, physical therapist Leslie Waltke walks us through a move called the ...

Advisory committee deliberations focused on causal attribution in a single-arm study and whether clinical benefit can be distinguished from nivolumab effect, despite favorable response durability ...

FDA authorization moves ^177Lu-PSMA radioligand therapy into the metastatic hormone-sensitive setting for PSMA-positive disease, paired with an ARPI such as abiraterone, apalutamide, enzalutamide, or ...

Unfiltered writing enabled meaning-making and emotional regulation after testicular cancer, while also functioning as informal psychosocial support for readers seeking normalization and reassurance.

After two cancer diagnoses, one survivor reflects on fear, healing, and why moving beyond the "battle" metaphor brought a new perspective.

Dr. Ajay Nooka discusses the MonumenTAL-6 trial and explains what the promising Tecvayli plus Talvey results could mean for patients with relapsed multiple myeloma. The phase 3 MonumenTAL-6 trial ...

Post hoc TOPAZ-1 analysis demonstrated sustained OS improvement with durvalumab+GemCis, translating to a 25% lower risk of death versus placebo+GemCis. Longer-term landmark survival favored durvalumab ...